bifeprunox has been researched along with gr 218231 in 1 studies
Studies (bifeprunox) | Trials (bifeprunox) | Recent Studies (post-2010) (bifeprunox) | Studies (gr 218231) | Trials (gr 218231) | Recent Studies (post-2010) (gr 218231) |
---|---|---|---|---|---|
30 | 1 | 12 | 6 | 0 | 0 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arnt, J; Bétry, C; Etievant, A; Haddjeri, N | 1 |
1 other study(ies) available for bifeprunox and gr 218231
Article | Year |
---|---|
Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Topics: Action Potentials; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Indoles; Male; Neurons; Piperazines; Piperidines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Sulfones; Tetrahydronaphthalenes; Ventral Tegmental Area | 2009 |